ALN-6400

DRUG2 trials

Sponsors

Alnylam Pharmaceuticals

Conditions

Heavy Menstrual Bleeding (HMB)Hereditary Hemorrhagic TelangiectasiaVon Willebrand Disease (VWD)

Phase 1

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Active, not recruitingNCT06659640

Alnylam PharmaceuticalsHereditary Hemorrhagic Telangiectasia

Start: 2024-11-07End: 2028-06-22Updated: 2026-09-16

Phase 2

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

RecruitingNCT07575308

Alnylam PharmaceuticalsHeavy Menstrual Bleeding (HMB), Von Willebrand Disease (VWD)

Start: 2026-07-30End: 2028-11-29Target: 24Updated: 2026-09-18

Related Papers

Hepatic plasminogen lowering with a galnac-conjugated siRNA reduces plasmin generation and fibrinolysis but has no effect on thrombin generation in rats and mice

Blood2025-11-03